













Key Operational Measures	2003	2004	2005	Target 20	006 <sup>1</sup>	Actual 2006
Organic Revenue Growth	-2%	1%	2%	2-3%	$\checkmark$	3%
Ordinary EBITA Margin	18%	16%	16%	16.5-17.0%	$\checkmark$	17%
Cash Conversion	109%	126%	106%	95-105%	$\checkmark$	100%
Key Financial Measures						
Free Cash Flow	€393 mln	€456 mln	€351 mln	> €350 mln	$\checkmark$	€443 mln
ROIC % <sup>2</sup>	7%	7%	7%	7%	$\checkmark$	7%
Ordinary Diluted EPS	€1.18	€1.02	€1.06	€1.18-€1.23	$\checkmark$	€1.23







	Resu	llts							
Organ the year	0	wth of 5.	9% in Q4	and 5.0%	for			La	w & Business 31%
custo	mer de		iting cont r softwar raries		ong				
growt innov	th thro ation,	ugh incre Iaunch o	ed solid o eased pro f several ved reten	duct online	Acc	ax & ounting 69%			
Maint signif	ained icant i	strong ma nvestmer	argins de: nts in nev	spite v product	S,				
.Net t	techno	logy and	shared se	ervices		Q4	05/Q4 06 Ch	ange (millior	ıs)
Millions		Q4 06	FY 06	Q4 05	FY 05	Organic	Acquisition / Disposal	Currency	Total
Revenues	(USD) (EUR)	231 179	849 678	197 165	775 621	12 10	20 17	2 (13)	34 14
	(USD)	26	162 131	29 24	155 122	0 0	(3) (2)	0 (2)	(3)
Ord. EBITA	(USD) (EUR)	20							(4)















	irket growth			
Key Operationa	I Metrics (US market) <sup>1</sup>	% Growth (05-06)		
Publishing Invento	ory Growth	6.8%		
Publishing Retent	ion Increase	2.8%		
Publishing Revenu	Publishing Revenue Growth - ARM			
Software Inventor	Software Inventory Growth			
Software Revenue	tware Revenue Growth - Tax			
Software Revenue	e Growth - Non-tax <sup>2</sup>	32.4%		
Industry Leadership	<ul> <li>20 products on Accounting Today "</li> <li>Industry Innovation Award for Pros 100 of top 100 accounting firms are</li> <li>95%+ retention on tax software</li> </ul>	ystem fx Scan		
	Kleinrock and TaxWise businesses with full year revenues 2005 and 2006			













	2003		20	04	20	05	20	06	То	tal
EUR Million	Original Target	Actual	Original Target	Actual	Original Target	Actual	Original Target	Actual	Original Target	Guidance
Product development spend	N/A	200	200 + 50 (CC=235)	220	200 + 70 (CC=255)	250	270	272	± 800 (incr. 200 3 year period)	± 800 (incr. 200 3 year period)
Non- exceptional restructuring expenses	N/A	N/A	40	25	30	42	30	39	± 215	± 260
Exceptional restructuring expenses	100	96	40	44	10	20	-	-	1 1 2 1 3	
FTE reductions	500	521	500	724	400	358	200	216	± 1600	± 1800
Total cost savings	20	29	40	70	80	100	120	128	100-110	160 run-rate



T	Divisional Outlook 2007		
		Organic Revenue Growth	
	💽 Health	2-3%	
	CFS	5-7%	
	San Tal	4-6%	
	LTRE	2-4%	
	Education	2-4%	
	Wolters Kluwer	4%	
	UK is included in the TAL division as of 2007		
(	Wolters Kluwer 200	16 Results February 28, 2007 Amsterdar	m 28

Key Operational Measures	2003	2004	2005	2006	2007 <sup>1</sup>
Organic Revenue Growth	-2%	1%	2%	3%	4%
Ordinary EBITA Margin	18%	16%	16%	17%	19-20%
Cash Conversion	109%	126%	106%	100%	95-105%
Key Financial Measures					
Free Cash Flow	€393 mln	€456 mln	€351 mln	€443 mln	± €450 ml
ROIC % <sup>2</sup>	7%	7%	7%	7%	> WACC3
Ordinary Diluted EPS	€1.18	€1.02	€1.06	€1.23	€1.45-€1.5





EUR Million	2006	2005	Actual Currencies %	Constant Currencies %	Organi Growtl %
Revenues	3,693	3,374	9%	10%	3%
Ordinary EBITA	618	533	16%	16%	
Ordinary EBITA margin %	16.7	15.8			
Ordinary Net Income	387	327	19%	18%	
Ordinary diluted EPS	€1.23	€1.06	16%	15%	
Free cash flow	443	351	26%		

EUR Million	2006	2005			
Revenues	3,693	3,374			2006
Ordinary EBITA	618	533	EUR Millions	2006 Revenues	Ordinar EBITA
Ordinary EBITA margin %	16.7	15.8	Health	823	120
Exceptional expense	0	(20)	CFS	534	116
EBITA	618	513	TAL	678	131
EBITA margin %	16.7	15.2	LTRE	1,342	228
Amortization	(121)	(81)	Education	316	62
Operating profit	497	432	Corporate Total	0	(39) 618
Income from investments	6	5	TOTAL	3,693	018
Financing results	(104)	(103)			
Results on disposals	9	4		evenues, EE	
Share of profit of associates	1	3		tion reflec	
Income (before tax)	409	341	annor tiza	d acquisitic	
Taxation on income	(87)	(80)			
Profit	322	261		nancing res	
Attributable to:			more en	icient capi	laistiu
Equity holders of the parent	321	260			
Minority interest	1	1			

EUR Million	2006	2005
Net income attributable to equity holders	321	260
Amortization of intangibles	121	81
Taxation on amortization	(47)	(29)
Results on disposals (after tax)	(8)	2
Exceptional restructuring expense (after tax)	-	13
Ordinary Net Income	387	327
Ordinary diluted EPS	€1.23	€1.06
Weighted average number of shares	307	302
Weighted average diluted shares	321	317

EUR Million	2006	2005	Increase in non-current assets
Total non-current assets	4,388	3,805	mainly related to acquisitions
Total current assets	1,265	1,635	Non-current liabilities lower as a result of shift of the €227
Total current liabilities	(2,834)	(2,562)	million bonds (maturity 2007) to current liabilities
Working capital	(1,569)	(927)	<ul> <li>Total equity increased due to</li> </ul>
Capital Employed	2,819	2,878	profit for the year, off-set by a
Total equity	1,196	1,099	weaker dollar, cash dividend and share buy back
Total non-current liabilities	1,232	1,436	
Deferred tax liabilities	192	80	Net Debt
Employee benefits	187	250	(stable gross debt at €2.2 billio
Provisions	12	13	2614 2821 2664
Total Financing	2,819	2,878	1900 1527 <sup>1637</sup>
Ratios	2006	2005	
Net debt / Equity	1.7	1.5	
Net debt / Ordinary EBITDA	2.9	2.6	1999 2000 2001 2002 2003 2004 2005

EUR Million	2006	2005	
Operating Profit	497	432	Increased Cash flow from operations du
Amortization & Depreciation	208	172	higher operating pr
Exceptional restructuring expense	-	20	Paid financing cost
Autonomous movements in working capital <sup>1</sup>	9	30	higher due to prem redemption (€33
Cash Flow from Operations	714	654	million) of converti bonds 2001 - 2006
Paid Financing costs	(126)	(99)	<ul> <li>Paid corporate inco</li> </ul>
Paid corporate income tax	(36)	(83)	tax lower due to re
Appropriation of restructuring provisions	(37)	(51)	
Share-based payments	17	12	
Other	3	(4)	
Cash Flow from Operating Activities	535	429	

EUR Million	2006	2005		
Cash Flow from Operating Activities	535	429		
Net capital expenditure on property, plant and equipment	(99)	(86)	Higher capita expenditure	
Net Acquisition spending	(773)	(357)	<ul> <li>Higher acquis spending is n Healthcare A</li> </ul>	
Net receipts from disposal activities	13	13	ProVation, AT Kleinrock and	
Dividends received	7	8		
Cash from derivatives	105	83	■ Cash from de realized swa €105 million	
Cash Flow from Investing Activities	(747)	(339)		
Exercise of share options	4	11	Movement in result of red	
Movement in (long-term) loans	(644)	(356)	the bonds re USD (multi-c	
New cash loans	682	9	credit facilit	
Movement in bank overdrafts	(22)	46	Dividend 200 versus 57% ov	
Dividend payments	(80)	(69)		
Repurchased shares	(19)	-		
Cash Flow from Financing Activities	(79)	(359)		

EUR Million	2006	2005	
Cash flow from operating activities	535	429	Free Cash Flow 2006
Cash flow from investment activities	(747)	(339)	Improved growth &
Cash flow from financing activities	(79)	(359)	margin
Net Cash Flow	(291)	(269)	Reduction in corpor tax paid
Cash and cash equivalents as at Jan. 1	428	687	Off-set by:
Exchange differences on cash equivalents	s 1	10	Higher paid financing and f
Cash and Cash Equivalents as at Dec. 31	138	428	costs mainly due to premium redemptic convertible bonds
Cash flow from operating activities	535	429	Higher Capex spend
Capital expenditure fixed assets	(99)	(86)	] [
Dividends received	7	8	
Free Cash Flow	443	351	

EUR Million	2006	2005	06/05	
Inventories	(6)	17	(23)	Strong Wor Capital Manad
Trade debtors	(69)	(63)	(6)	Capital Manag
Other debtors	11	23	(12)	149
Deferred income	34	21	13	
Trade creditors	9	49	(40)	34 30
Other short-term liabilities	40	(17)	57	2003 2004 200
Increase/(Decrease)	19 <sup>1</sup>	30	(11)	

	2006 Main Acquisitions						
		Healthcare Analytics (NDC IM)     ProVation Medical Inc.	January 2006 January 2006				
	CFS	• GulfPak	August 2006				
		<ul> <li>Sage Practice Solutions line</li> <li>ATX/Kleinrock</li> <li>TaxWise</li> </ul>	January 2006 August 2006 October 2006				
		Carl Heymanns Verlag	May 2006				
	🛃 Total	Annualized revenues of €252 million	2006 revenue contribution of €187 million				
4	<ul> <li>Total net cash acquisition spending €773 million; including earn-outs of past deals</li> <li>Total consideration on acquisitions was €829 million</li> <li>All acquisitions are accretive to ordinary EPS in year 1</li> <li>All acquisitions expected to cover their cost of capital within 3-5 years</li> </ul>						
	🞐 Wolters Kluwer	2006 Results	February 28, 2007 Amsterdam 40				



Key Operational Measures	Actual 2006	Target 2007 <sup>1</sup>	Improved growth & margin
Organic revenue growth	3.2%	4%	Off-set by:
Ordinary EBITA margin	16.7%	19-20%	Increased Capex spendin to 3% of revenues
Cash conversion	100%	95-105%	Flat working capital; no
Key Financial Measures			further improvement in 2007
Free cash flow	€443 mIn	± €450 mln	Income tax paid returning to normal levels
ROIC % <sup>2</sup>	7.2%	> WACC <sup>3</sup>	to normal levels
Ordinary diluted EPS	€1.23	€1.45 - €1.55	
			Ordinary diluted EPS Double digit growth





Key Operational Measures	2003	2004	2005	2006	20071	Beyond
Organic Revenue Growth	-2%	1%	2%	3%	4%	4-59
Ordinary EBITA Margin	18%	16%	16%	17%	19-20%	Continu improve
Cash Conversion	109%	126%	106%	100%	95-105%	95-10
Key Financial Measures						
Free Cash Flow	€393 mln	€456 mln	€351 mln	€443 mln	± €450 mln	> €450
ROIC % <sup>2</sup>	7%	7%	7%	7%	> WACC3	> WAC
Ordinary Diluted EPS	€1.18	€1.02	€1.06	€1.23	€1.45-€1.55	Double o growt





I	Calei	ndar			
	AR	March 22, 2007			
	AGM	April 20, 2007			
all.	Q1	May 9, 2007			
	Q2	August 1, 2007			
U	Q3	November 7, 2007			
ľ	-				
(	🥑 Wolte	ers Kluwer	2006 Results	February 28, 2007 Amsterdam	48

